Northeast Pharmaceutical Group Co Ltd Net Assets

Latest as of June 2026: CN¥5.65 Billion CNY ≈ $827.13 Million USD

Northeast Pharmaceutical Group Co Ltd net assets. Based on the latest financial reports, Northeast Pharmaceutical Group Co Ltd (000597) has net assets worth CN¥5.65 Billion CNY (≈ $827.13 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.58 Billion ≈ $1.99 Billion USD) and total liabilities (CN¥7.93 Billion ≈ $1.16 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Northeast Pharmaceutical Group Co Ltd (000597) net asset momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥5.65 Billion
% of Total Assets	41.63%
Annual Growth Rate	8.23%
5-Year Change	32.14%
10-Year Change	132.92%
Growth Volatility	22.43

Net Assets of Northeast Pharmaceutical Group Co Ltd (1993–2025)

Net assets of Northeast Pharmaceutical Group Co Ltd from 1993 to 2025. This chart illustrates how Northeast Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. See how leveraged is Northeast Pharmaceutical Group Co Ltd's balance sheet to measure how much of total assets are equity-financed.

Annual Net Assets for Northeast Pharmaceutical Group Co Ltd (1993–2025)

The table below shows the annual net assets of Northeast Pharmaceutical Group Co Ltd from 1993 to 2025. For live market cap and overall valuation, see Northeast Pharmaceutical Group Co Ltd (000597) total market value.

Year	Net Assets	Change
2025-12-31	CN¥5.67 Billion ≈ $829.59 Million	+1.79%
2024-12-31	CN¥5.57 Billion ≈ $815.01 Million	+7.97%
2023-12-31	CN¥5.16 Billion ≈ $754.89 Million	+9.45%
2022-12-31	CN¥4.71 Billion ≈ $689.70 Million	+9.86%
2021-12-31	CN¥4.29 Billion ≈ $627.80 Million	+4.08%
2020-12-31	CN¥4.12 Billion ≈ $603.21 Million	+5.22%
2019-12-31	CN¥3.92 Billion ≈ $573.30 Million	+9.05%
2018-12-31	CN¥3.59 Billion ≈ $525.75 Million	+41.01%
2017-12-31	CN¥2.55 Billion ≈ $372.85 Million	+4.68%
2016-12-31	CN¥2.43 Billion ≈ $356.17 Million	+1.37%
2015-12-31	CN¥2.40 Billion ≈ $351.34 Million	-13.04%
2014-12-31	CN¥2.76 Billion ≈ $404.05 Million	+72.68%
2013-12-31	CN¥1.60 Billion ≈ $233.99 Million	-8.64%
2012-12-31	CN¥1.75 Billion ≈ $256.13 Million	+0.43%
2011-12-31	CN¥1.74 Billion ≈ $255.03 Million	-15.62%
2010-12-31	CN¥2.07 Billion ≈ $302.24 Million	+0.58%
2009-12-31	CN¥2.05 Billion ≈ $300.50 Million	+30.42%
2008-12-31	CN¥1.57 Billion ≈ $230.40 Million	+77.07%
2007-12-31	CN¥889.22 Million ≈ $130.12 Million	-4.13%
2006-12-31	CN¥927.49 Million ≈ $135.72 Million	+3.05%
2005-12-31	CN¥900.07 Million ≈ $131.71 Million	+1.82%
2004-12-31	CN¥884.02 Million ≈ $129.36 Million	+1.58%
2003-12-31	CN¥870.26 Million ≈ $127.35 Million	-0.35%
2002-12-31	CN¥873.28 Million ≈ $127.79 Million	-1.14%
2001-12-31	CN¥883.36 Million ≈ $129.26 Million	-2.45%
2000-12-31	CN¥905.53 Million ≈ $132.51 Million	+4.12%
1999-12-31	CN¥869.73 Million ≈ $127.27 Million	-12.95%
1998-12-31	CN¥999.14 Million ≈ $146.21 Million	+6.82%
1997-12-31	CN¥935.36 Million ≈ $136.87 Million	-5.95%
1996-12-31	CN¥994.58 Million ≈ $145.54 Million	+28.32%
1995-12-31	CN¥775.11 Million ≈ $113.42 Million	+59.11%
1994-12-31	CN¥487.14 Million ≈ $71.28 Million	+8.00%
1993-12-31	CN¥451.06 Million ≈ $66.00 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Northeast Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 3020.1% over the analyzed period, indicating profitable operations and earnings retention.

Northeast Pharmaceutical Group Co Ltd Net Assets Breakdown (December 2025)

Northeast Pharmaceutical Group Co Ltd net assets breakdown by equity component as of December 2025.

Component	Amount	Percentage
Retained Earnings	CN¥1.37 Billion	24.83%
Other Components	CN¥4.16 Billion	75.17%
Total Equity	CN¥5.53 Billion	100.00%

Northeast Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Northeast Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company	Market Cap
Shunfa Hengye Corp SHE:000631	$935.64 Million
Critical Metals Corp. Ordinary Shares NASDAQ:CRML	$935.68 Million
Drägerwerk AG & Co. KGaA XETRA:DRW8	$935.99 Million
Beijing Hotgen Biotech Co Ltd SHG:688068	$936.06 Million
Middlesex Water Company NASDAQ:MSEX	$935.05 Million
Edgewell Personal Care Co NYSE:EPC	$934.53 Million
HMC Capital Ltd AU:HMC	$934.25 Million
IRB-Brasil Resseguros S.A. SA:IRBR3	$934.08 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Northeast Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 5,321,613,000 to 5,529,861,665, a change of 208,248,665 (3.9%).
Net income of 260,070,457 contributed positively to equity growth.
Dividend payments of 196,902,897 reduced retained earnings.
Other comprehensive income decreased equity by 8,970,433.
Other factors increased equity by 154,051,538.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥260.07 Million	+4.7%
Dividends Paid	CN¥196.90 Million	-3.56%
Other Comprehensive Income	CN¥-8.97 Million	-0.16%
Other Changes	CN¥154.05 Million	+2.79%
Total Change	CN¥-	3.91%

Book Value vs Market Value Analysis

This analysis compares Northeast Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.16x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 6.72x to 1.16x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1993-12-31	CN¥0.67	CN¥4.48	x
1994-12-31	CN¥0.72	CN¥4.48	x
1995-12-31	CN¥1.15	CN¥4.48	x
1996-12-31	CN¥1.47	CN¥4.48	x
1997-12-31	CN¥1.38	CN¥4.48	x
1998-12-31	CN¥1.22	CN¥4.48	x
1999-12-31	CN¥1.29	CN¥4.48	x
2000-12-31	CN¥1.29	CN¥4.48	x
2001-12-31	CN¥1.27	CN¥4.48	x
2002-12-31	CN¥1.29	CN¥4.48	x
2003-12-31	CN¥1.29	CN¥4.48	x
2004-12-31	CN¥1.31	CN¥4.48	x
2005-12-31	CN¥1.33	CN¥4.48	x
2006-12-31	CN¥1.38	CN¥4.48	x
2007-12-31	CN¥1.31	CN¥4.48	x
2008-12-31	CN¥2.29	CN¥4.48	x
2009-12-31	CN¥2.73	CN¥4.48	x
2010-12-31	CN¥2.73	CN¥4.48	x
2011-12-31	CN¥2.23	CN¥4.48	x
2012-12-31	CN¥1.85	CN¥4.48	x
2013-12-31	CN¥2.03	CN¥4.48	x
2014-12-31	CN¥3.03	CN¥4.48	x
2015-12-31	CN¥2.17	CN¥4.48	x
2016-12-31	CN¥2.19	CN¥4.48	x
2017-12-31	CN¥2.30	CN¥4.48	x
2018-12-31	CN¥2.86	CN¥4.48	x
2019-12-31	CN¥3.01	CN¥4.48	x
2020-12-31	CN¥3.25	CN¥4.48	x
2021-12-31	CN¥3.07	CN¥4.48	x
2022-12-31	CN¥3.38	CN¥4.48	x
2023-12-31	CN¥3.48	CN¥4.48	x
2024-12-31	CN¥3.72	CN¥4.48	x
2025-12-31	CN¥3.87	CN¥4.48	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Northeast Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 4.70%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.68%
• Asset Turnover: 0.55x
• Equity Multiplier: 2.33x
Recent ROE (4.70%) is above the historical average (2.87%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1993	9.76%	4.39%	0.67x	3.33x	CN¥-1.09 Million
1994	12.98%	6.76%	0.58x	3.28x	CN¥14.51 Million
1995	6.08%	4.49%	0.43x	3.16x	CN¥-30.41 Million
1996	2.01%	1.71%	0.38x	3.11x	CN¥-79.51 Million
1997	-7.40%	-9.14%	0.35x	2.32x	CN¥-162.78 Million
1998	4.31%	4.67%	0.29x	3.14x	CN¥-46.90 Million
1999	4.99%	4.29%	0.39x	2.99x	CN¥-43.58 Million
2000	2.23%	1.63%	0.45x	3.06x	CN¥-67.73 Million
2001	0.44%	0.27%	0.52x	3.20x	CN¥-82.32 Million
2002	1.11%	0.69%	0.52x	3.07x	CN¥-77.65 Million
2003	1.00%	0.54%	0.64x	2.90x	CN¥-78.34 Million
2004	0.68%	0.37%	0.67x	2.75x	CN¥-82.41 Million
2005	1.38%	0.68%	0.80x	2.55x	CN¥-77.59 Million
2006	2.65%	1.17%	0.95x	2.38x	CN¥-68.16 Million
2007	5.36%	1.28%	1.21x	3.44x	CN¥-41.22 Million
2008	22.77%	7.76%	1.12x	2.61x	CN¥200.75 Million
2009	23.58%	9.35%	0.84x	3.01x	CN¥274.16 Million
2010	2.64%	1.11%	0.86x	2.77x	CN¥-148.89 Million
2011	-23.79%	-10.15%	0.66x	3.54x	CN¥-560.00 Million
2012	0.49%	0.21%	0.64x	3.60x	CN¥-158.42 Million
2013	-11.11%	-4.31%	0.51x	5.02x	CN¥-317.30 Million
2014	3.27%	2.01%	0.51x	3.22x	CN¥-179.36 Million
2015	-16.79%	-10.02%	0.44x	3.80x	CN¥-613.28 Million
2016	1.03%	0.49%	0.49x	4.23x	CN¥-207.66 Million
2017	4.89%	2.10%	0.54x	4.35x	CN¥-124.37 Million
2018	5.62%	2.61%	0.64x	3.38x	CN¥-151.88 Million
2019	4.57%	2.12%	0.66x	3.29x	CN¥-207.10 Million
2020	0.31%	0.17%	0.61x	3.06x	CN¥-385.80 Million
2021	2.39%	1.22%	0.62x	3.18x	CN¥-315.35 Million
2022	7.68%	3.98%	0.64x	3.03x	CN¥-105.68 Million
2023	7.19%	4.35%	0.54x	3.06x	CN¥-140.37 Million
2024	7.70%	5.46%	0.52x	2.71x	CN¥-122.31 Million
2025	4.70%	3.68%	0.55x	2.33x	CN¥-292.92 Million

Industry Comparison

This section compares Northeast Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $2,262,186,440
Average return on equity (ROE) among peers: 8.18%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Northeast Pharmaceutical Group Co Ltd (000597)	CN¥5.65 Billion	9.76%	1.40x	$935.44 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$902.62 Million	5.17%	3.60x	$492.82 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.56 Billion	7.90%	1.45x	$363.79 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$366.91 Million	9.97%	0.26x	$4.71 Billion
Livzon Pharmaceutical Group Inc (000513)	$14.91 Billion	13.83%	0.64x	$2.63 Billion
Wedge Industrial Co Ltd (000534)	$654.70 Million	1.92%	0.87x	$1.28 Billion
Yunnan Baiyao Group Co Ltd (000538)	$35.11 Million	18.13%	0.80x	$14.36 Billion
Hainan Haiyao Co Ltd (000566)	$317.39 Million	7.74%	0.74x	$766.98 Million
Tus Pharmaceutical Group Co Ltd (000590)	$268.54 Million	1.60%	1.47x	$273.68 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$1.35 Billion	7.34%	0.44x	$3.04 Billion

About Northeast Pharmaceutical Group Co Ltd

SHE:000597 China Drug Manufacturers - Specialty & Generic

Market Cap

$935.44 Million

CN¥6.39 Billion CNY

Market Cap Rank

#8893 Global

#2101 in China

Share Price

CN¥4.48

Change (1 day)

+1.59%

52-Week Range

CN¥4.20 - CN¥5.86

All Time High

CN¥133.00